The Nomura business research company has praised the management of Hungary's Richter Gedeon for the drug company's good results in a generally lethargic Hungarian pharmaceuticals market, reports MTI Econews.
Nomura recently upgraded its rating for Richter Gedeon shares and believes that significant growth on a share price of 6,110 per share on the Budapest Stock Exchange in mid-May can be expected. It is recommending purchase of RG shares.
It is noted that stockpiling of drugs in the first quarter of 1996 in Hungary, ahead of a planned price increase, may set back the fast growth in sales later this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze